Patricia Vold Pepper1, Douglas K Owens. 1. Department of General Internal Medicine, Naval Medical Center San Diego, 34800 Bob Wilson Drive, Box 130, San Diego, CA 92134-5000, USA. pvpepper@nmcsd.med.navy.mil
Abstract
OBJECTIVES: Routine vaccination for Streptococcus pneumoniae has been recommended as a cost-effective measure for elderly and immunocompromised patients, yet no analysis has been performed for healthy younger adults in America. The authors evaluated the cost-effectiveness of the pneumococcal vaccine and determined the net health benefits conferred for the healthy young adult population. METHODS: The authors developed a decision model to compare the health and economic outcomes of vaccinate versus do not vaccinate for S. pneumoniae. RESULTS: Vaccinating patients for S. pneumoniae generates benefits that are dependent on incidence rates and the efficacy of the vaccine. In the 22-year-old patient with a pneumonia incidence of 0.3/1000, the vaccine would need to be > 71 percent effective for the vaccination strategy to cost less than $50,000/QALY gained. At an incidence of 0.4/1000, the threshold efficacy is 53 percent, whereas at 0.5/1000 it is 43 percent. In the 35-year-old patient where the incidence of pneumococcal pneumonia is higher (0.85/1000), the vaccine would be cost-effective with an efficacy as low as 30 percent. CONCLUSIONS: Use of the S. pneumoniae vaccine in young adults would provide modest reductions in pneumonia-associated morbidity and mortality. Vaccination of young adults is moderately expensive unless vaccine efficacy is above 50% to 60%. In 35-year-old adults, use of the vaccine is cost-effective even with moderate efficacy.
OBJECTIVES: Routine vaccination for Streptococcus pneumoniae has been recommended as a cost-effective measure for elderly and immunocompromised patients, yet no analysis has been performed for healthy younger adults in America. The authors evaluated the cost-effectiveness of the pneumococcal vaccine and determined the net health benefits conferred for the healthy young adult population. METHODS: The authors developed a decision model to compare the health and economic outcomes of vaccinate versus do not vaccinate for S. pneumoniae. RESULTS: Vaccinating patients for S. pneumoniae generates benefits that are dependent on incidence rates and the efficacy of the vaccine. In the 22-year-old patient with a pneumonia incidence of 0.3/1000, the vaccine would need to be > 71 percent effective for the vaccination strategy to cost less than $50,000/QALY gained. At an incidence of 0.4/1000, the threshold efficacy is 53 percent, whereas at 0.5/1000 it is 43 percent. In the 35-year-old patient where the incidence of pneumococcal pneumonia is higher (0.85/1000), the vaccine would be cost-effective with an efficacy as low as 30 percent. CONCLUSIONS: Use of the S. pneumoniae vaccine in young adults would provide modest reductions in pneumonia-associated morbidity and mortality. Vaccination of young adults is moderately expensive unless vaccine efficacy is above 50% to 60%. In 35-year-old adults, use of the vaccine is cost-effective even with moderate efficacy.
Authors: Andrew J Leidner; Neil Murthy; Harrell W Chesson; Matthew Biggerstaff; Charles Stoecker; Aaron M Harris; Anna Acosta; Kathleen Dooling; Carolyn B Bridges Journal: Vaccine Date: 2018-12-04 Impact factor: 3.641
Authors: Patricia A Zrelak; Garth H Utter; Kathryn M McDonald; Robert L Houchens; Sheryl M Davies; Halcyon G Skinner; Pamela L Owens; Patrick S Romano Journal: Health Serv Res Date: 2022-01-09 Impact factor: 3.734
Authors: Bruce R Schackman; Callie A Scott; Rochelle P Walensky; Elena Losina; Kenneth A Freedberg; Paul E Sax Journal: AIDS Date: 2008-10-01 Impact factor: 4.177
Authors: Paul E Sax; Alexis Sypek; Bethany K Berkowitz; Bethany L Morris; Elena Losina; A David Paltiel; Kathleen A Kelly; George R Seage; Rochelle P Walensky; Milton C Weinstein; Joseph Eron; Kenneth A Freedberg Journal: PLoS One Date: 2014-11-14 Impact factor: 3.240